Testing the ability to sense temperatures and mechanical forces could help predict when symptoms will appear for people who carry…
Articles by Marisa Wexler, MS
Treatment with Vyndaqel (tafamidis) reduces signs of heart damage for most people with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM)…
Eplontersen continues to safely and effectively ease symptoms and improve quality of life for people with familial amyloid…
Treatment with Onpattro (patisiran) for 1.5 years leads to sustained reductions in disability progression among people with ATTR amyloidosis…
Treatment with Onpattro (patisiran) or Amvuttra (vutrisiran) leads to a reduction in blood levels of neurofilament light chain…
People with hereditary transthyretin amyloidosis (hATTR) who are treated with a combination of therapies appear to have better health outcomes…
In the U.S., one-third of people with hereditary transthyretin amyloidosis (hATTR) — a group of disorders that includes familial amyloid…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Ionis Pharmaceuticals seeking approval…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Alnylam Pharmaceuticals seeking the approval…
Most people with late-onset familial amyloid polyneuropathy (FAP) experience pain as a result of nerve damage, referred to as…